This study describes the maturation of sirolimus clearance in a cohort of very young pediatric patients with vascular anomalies. The relationship between allometrically scaled in vivo clearance and age was described by the Emax model in patients aged 1 month to 2 years. Consistent with the observed increase, in vitro intrinsic clearance of sirolimus using pediatric liver microsomes showed a sim...

Objectives The aim of this study was to observe the impact of sirolimus on proteinuria in streptozotocin (STZ) induced diabetic rats. Materials and Methods Rats were given a single injection of STZ to induce diabetic rat model. Rats' 24 hr urine was collected to test, urinary and the kidney tissues were harvested at the 8th and 20th weeks, respectively. Podocyte morphological changes were exa...

BACKGROUND Although high-performance liquid chromatography (HPLC) is the method of choice for blood sirolimus determination, the microparticle enzyme immunoassay (MEIA) run on the IMx analyser is widely used in therapeutic monitoring of this immunosuppressant agent. The aim of our study was to evaluate the possible determination of sirolimus using the fluorescence polarization immunoassay (FPIA...

OBJECTIVES/HYPOTHESIS To evaluate antitumor efficacy of the generic mammalian target of rapamycin (mTOR) inhibitor sirolimus in preclinical animal models of head and neck squamous cell carcinoma (HNSCC) and compare its effects with those of the patented analogue temsirolimus. STUDY DESIGN In vivo study. METHODS To develop xenograft established tumor model (ETM) of HNSCC, FaDu cells were inj...

BACKGROUND Lymphangioleiomyomatosis (LAM) is a rare disease caused by dysregulated activation of the mammalian target of rapamycin (mTOR). Sirolimus, an inhibitor of mTOR, has been reported to decrease the size of angiomyolipomas and stabilize pulmonary function in patients with LAM. However, the optimal dose for the treatment of LAM remains unclear. METHODS We conducted a retrospective, obse...

BACKGROUND Lymphangioleiomyomatosis (LAM) is a rare lung disease characterised by progressive airflow obstruction. No effective medical treatment is available but therapy with sirolimus has shown some promise. The aim of this observational study was to evaluate sirolimus in progressive LAM. METHODS Sirolimus (trough level 5 - 10 ng/ml) was administered to ten female patients (42.4 ± 11.9 year...

Objective: To explore and summarize the effect of sirolimus on ischemic-type biliary lesions (ITBL) after liver transplantation. Methods: A retrospective study was carried out on 52 patients using sirolimus for biliary complications after liver transplantation from 2004 to 2016 in our hospital. Serum alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin, glutamyl endopeptida...

OBJECTIVES The long-term use of cyclosporine always contributes to chronic renal allograft dysfunction. Converting from cyclosporine to sirolimus and reducing cyclosporine dosage under high mycophenolate mofetil levels are 2 common therapies. Their efficacy and safety have not been compared in Chinese patients. MATERIALS AND METHODS In this prospective, open label, randomized study, 51 kidney...

OBJECTIVES The aim of this study was to compare the effects of paclitaxel, sirolimus, and everolimus on the senescent phenotype in human endothelial cells, and to further investigate possible involvement of mammalian sirtuin 1 (Sirt1) down-regulation as a mechanism. BACKGROUND Endothelial cell senescence may play a role in impaired re-endothelialization after drug-eluting stent (DES) implanta...

With the increasing success of liver transplantation and the proven effectiveness of highly active retroviral therapy in HIV-positive patients, liver transplantation has been performed successfully in selected HIV-positive recipients with CD4 and an HIV viral load response to highly active antiretroviral therapy. In these patients, an interaction between a protease inhibitor (nelfinavir) and ta...